Vtesse
Gaithersburg, United States · Founded 2015 · $42.0M raised
- Headquarters
- Gaithersburg, Maryland
- Employees
- 1–10
- Founded
- 2015
- Business Model
- B2B
- Total Funding
- $42.0M
- Last Round
- $17.0M Extension RoundJul 2016
- Rounds
- 2
About
Vtesse was a rare disease biotechnology company founded around 2014-2015 as a spin-off from NIH/NCATS to develop cyclodextrin (hydroxypropyl-beta-cyclodextrin, VTS-270) as a treatment for Niemann-Pick Type C1 (NPC), a fatal lysosomal storage disorder. The company partnered with NIH researchers to advance the asset through Phase 2b/3 clinical trials. Vtesse secured $25 million in early funding to bankroll NIH-led trials and support its own clinical development program. The company was subsequently acquired by Mallinckrodt Pharmaceuticals, which continued sponsoring the NPC clinical trial.
Summary
Vtesse is a Biotech company based in Gaithersburg, United States, founded in 2015. It has raised $42.0M in total across 2 rounds, most recently a $17.0M Extension Round round in Jul 2016. Investors include New Enterprise Associates, Pfizer Ventures and Lundbeckfonden BioCapital.
Funding History
Jul 2016
Sign up to see all 2 rounds
Series A through Extension Round — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
China's leading blood products manufacturer
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Specialty pharmaceutical company
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/vtesse"><img src="https://indexed.vc/api/badge/company/vtesse" alt="Vtesse on Indexed.vc" width="260" height="76" /></a>